Immunotherapy in Miscellaneous Medical Disorders Graves Ophthalmopathy, Asthma, and Regional Painful Syndrome

Medical Clinics of North America

Volumn 96, Issue 3, 2012, Pages 635-654

  Gonzales, Michael ^a   Fratianni, Carmel ^b   Mamillapali, Chaitanya ^b   Khardori, Romesh ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allergy; Asthma; Graves'; Ophthalmopathy; Painful neuropathy

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; ETANERCEPT; GLUCOCORTICOID; IMATINIB; IMMUNOGLOBULIN; INTERLEUKIN 16; INTERLEUKIN 6; LIOTHYRONINE; METHYLPREDNISOLONE; OCTREOTIDE; OMALIZUMAB; PENTOXIFYLLINE; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PREDNISONE; RADIOACTIVE IODINE; RANTES; RITUXIMAB; SELENIUM; SOMATOMEDIN C; THIAMAZOLE; THYROTROPIN RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TRIAMCINOLONE ACETATE; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADIPOCYTE; ARTHRALGIA; ASTHMA; BLURRED VISION; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CLINICAL FEATURE; COST OF ILLNESS; CYTOKINE RELEASE; DIPLOPIA; DRUG MEGADOSE; ENDOCRINE OPHTHALMOPATHY; ENTERITIS; EPIPHORA; FIBROBLAST; FOLLOW UP; GRAVES DISEASE; HISTOLOGY; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INCIDENCE; INTERMETHOD COMPARISON; IRIDOCYCLITIS; LIVER TOXICITY; MONOTHERAPY; ORBIT INFLAMMATION; PAIN; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; REGIONAL PAINFUL SYNDROME; REVIEW; RISK FACTOR; SERUM SICKNESS; SEX RATIO; SMOKING; STEROID THERAPY; THYROIDECTOMY; TISSUE EXPANSION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

ALLERGENS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIOXIDANTS; ASTHMA; AZATHIOPRINE; COMPLEX REGIONAL PAIN SYNDROMES; CYCLOSPORINE; DECOMPRESSION, SURGICAL; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; OCTREOTIDE; ORBIT; PIPERAZINES; PYRIDONES; PYRIMIDINES; RADIOTHERAPY DOSAGE; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SELENIUM;

EID: 84862331738     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.04.013     Document Type: Review

References (99)

1. Lazarus J.H. Acute pretibial myxedema, Graves' disease and radioiodine therapy. Clin Endocrinol 1995, 42:661.
2. Weetman A.P. Graves' disease. N Engl J Med 2000, 343:1236-1248.
3. Ludgate M., Baker G. Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease. Clin Exp Immunol 2002, 127:193-198.
4. Wiersinga W.M., Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 2002, 12(10):855-860.
5. Perros P., Weightman D.R., Crombie A.L., et al. Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol (Copenh) 1990, 122(1):8-12.
6. Goldstein S.M., Katowitz W.R., Moshang T., et al. Pediatric thyroid-associated orbitopathy: the Children's Hospital of Philadelphia experience and literature review. Thyroid 2008, 18(9):997-999.
7. Smith T.J., Koumas L., Gagnon A., et al. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2002, 87:385-392.
8. Smith T.J. Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid-associated ophthalmopathy. Thyroid 2002, 12:197-203.
9. Bahn R.S., Gorman C.A., Woloschak G.E., et al. Human retroocular fibroblasts in vitro: a model for the study of Graves' ophthalmopathy. J Clin Endocrinol Metab 1987, 65:665-670.
10. Wang H.S., Cao H.J., Winn V.D., et al. Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts. J Biol Chem 1996, 271:22718-22728.
11. Cao H.J., Wang H.S., Zhang Y., et al. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem 1998, 273:29615-29625.
12. Smith T.J., Bahn R.S., Gorman C.A., et al. Stimulation of glycosaminoglycan accumulation by interferon gamma in cultured human retroocular fibroblasts. J Clin Endocrinol Metab 1991, 72:1169-1171.
13. Yang D., Hiromatsu Y., Hoshino T., et al. Dominant infiltration of T (H) 1-type CD4+ T cells at the retrobulbar space of patients with thyroid-associated ophthalmopathy. Thyroid 1999, 9:305-310.
14. Aniszewski J.P., Valyasevi R.W., Bahn R.S. Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy. J Clin Endocrinol Metab 2000, 85:776-780.
15. Bartalena L., Pinchera A., Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000, 21:168-199.
16. Marcocci C., Bartalena L., Bogozzi F., et al. Studies on the occurrence of ophthalmopathy in Graves' disease. Acta Endocrinol (Copenh) 1989, 120:473-478.
17. Bahn R.S. Assessment and management of the patient with Graves' opthalmopathy. Endocr Pract 1995, 1:172-178.
18. Bahn R.S., Bartley G.B., Gorman C.A. Emergency treatment of Graves' ophthalmopathy. Baillieres Clin Endocrinol Metab 1992, 6(1):95-105.
19. Prabhakar B.S., Bahn R.S., Smith T.J. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 2003, 24(6):802-835.
20. Perros P., Crombie A.L., Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 1995, 42(1):45.
21. Pichler R., Sonnberger M., Dorninger C., et al. Ga-68-DOTA-NOC PET/CT reveals active Graves' orbitopathy in a single extraorbital muscle. Clin Nucl Med 2011, 36(10):910-911.
22. Kahaly G.J. Recent developments in Graves' ophthalmopathy imaging. J Endocrinol Invest 2004, 27(3):254-258.
23. Avunduk A.M., Avunduk M.C., Pazarli H., et al. Immunohistochemical analysis of orbital connective tissue specimens of patients with active Graves ophthalmopathy. Curr Eye Res 2005, 30:631-638.
24. Wiersinga W.M., Prummel M.F. Pathogenesis of Graves' ophthalmopathy-current understanding. J Clin Endocrinol Metab 2001, 86(2):501-503.
25. Törring O., Tallstedt L., Wallin G., et al. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine-a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 1996, 81(8):2986-2993.
26. Träisk F., Tallstedt L., Abraham-Nordling M., et al. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 2009, 94(10):3700-3707. Thyroid Study Group of TT 96.
27. Tomlinson J.W., Durrani O.M., Bujalska I.J., et al. The role of 11beta-hydroxysteroid dehydrogenase 1 in adipogenesis in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2010, 95(1):398-406.
28. van Steensel L., Dik W.A. The orbital fibroblast: a key player and target for therapy in Graves' ophthalmopathy. Orbit 2010, 29(4):202-206.
29. Pritchard J., Horst N., Cruikshank W., et al. Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol 2002, 168(2):942-950.
30. Schall T.J., Bacon K., Toy K.J., et al. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990, 347:669-671.
31. Douglas R.S., Gianoukakis A.G., Kamat S., et al. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. J Immunol 2007, 178(5):3281-3287.
32. Douglas R.S., Naik V., Hwang C.J., et al. B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol 2008, 181(8):5768-5774.
33. Gianoukakis A.G., Smith T.J. Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy. Curr Opin Endocrinol Diabetes Obes 2008, 15(5):446-452.
34. Bartalena L., Baldeschi L., Dickinson A., et al. Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008, 158:273-285.
35. Werner S.C. Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab 1977, 44:203-204.
36. Wiersinga W.M. Immunosuppressive treatment of Graves' ophthalmopathy. Thyroid 1992, 2(3):229.
37. Ebner R., Devoto M.H., Weil D., et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol 2004, 88(11):1380-1386.
38. Zang S., Ponto K.A., Kahaly G.J. Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 2011, 96(2):320-332.
39. Marino M., Morabito E., Brunette M.R., et al. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 2004, 14:403-406.
40. van Geest R.J., Sasim I.V., Koppeschaar H.P., et al. Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol 2008, 158(2):229-237.
41. Tallstedt L., Lundell G., Tørring O., et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992, 326(26):1733.
42. Bartalena L., Marcocci C., Bogazzi F., et al. A relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998, 338(2):73.
43. Harvey R.D., Metcalfe R.A., Morteo C., et al. Acute pre-tibial myxoedema following radioiodine therapy for thyrotoxic Graves' disease. Clin Endocrinol (Oxf) 1995, 42(6):657.
44. McGregor A.M., Petersen M.M., Capiferri R., et al. Effects of radioiodine on thyrotrophin binding inhibiting immunoglobulins in Graves' disease. Clin Endocrinol (Oxf) 1979, 11(4):437.
45. Tallstedt L., Lundell G., Blomgren H., et al. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?. Eur J Endocrinol 1994, 130(5):494-497.
46. Lai A., Sassi L., Compri E., et al. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 2010, 95(3):1333-1337.
47. Wakelkamp I.M., Baldeschi L., Saeed P., et al. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf) 2005, 63:323-328.
48. Prummel M.F., Terwee C.B., Gerding M.N., et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab 2004, 89:15-20.
49. Gorman C.A., Garrity J.A., Fatourechi V., et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2001, 108:1523-1534.
50. Mourits M.P., van Kempen-Harteveld M.L., Garcia M.B., et al. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. Lancet 2000, 355:1505-1509.
51. Marquez S.D., Lum B.L., McDougall I.R., et al. Long-term results of irradiation for patients with progressive Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys 2001, 51(3):766-774.
52. Gerling J., Kommerell G., Henne K., et al. Retrobulbar irradiation for thyroid-associated orbitopathy: double-blind comparison between 2.4 and 16 Gy. Int J Radiat Oncol Biol Phys 2003, 55:182-189.
53. Kahaly G.J., Rosler H.P., Pitz S., et al. Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab 2000, 85:102-108.
54. Krassas G.E., Gogakos A. Thyroid-associated ophthalmopathy in juvenile Graves' disease-clinical, endocrine and therapeutic aspects. J Pediatr Endocrinol Metab 2006, 19(10):1193-1206.
55. Schaefer U., Hesselmann S., Micke O., et al. A long-term follow-up study after retro-orbital irradiation for Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys 2002, 52(1):192-197.
56. Prummel M.F., Mourits M.P., Blank L., et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993, 342(8877):949.
57. Ng C.M., Yuen H.K., Choi K.L., et al. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study. Hong Kong Med J 2005, 11:322-330.
58. Bartalena L., Marcocci C., Chiovato L., et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983, 56:1139-1144.
59. Marcocci C., Bartalena L., Bogazzi F., et al. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest 1991, 14:853-860.
60. Chang T.C., Liao S.L. Slow-release lanreotide in Graves' ophthalmopathy: a double-blind randomized, placebo-controlled clinical trial. J Endocrinol Invest 2006, 29(5):413-422.
61. Stan M.N., Garrity J.A., Bradley E.A., et al. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. J Clin Endocrinol Metab 2006, 91(12):4817-4824.
62. Kahaly G., Schrezenmeir J., Krause U., et al. Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 1986, 16:415-422.
63. Wiersinga W.M., Prummel M.F., Mourits M.P., et al. Classification of the eye changes of Graves' disease. Thyroid 1991, 1:357-360.
64. Paridaens D., van den Bosch W.A., van der Loos T.L., et al. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye 2005, 19:1286-1289.
65. Nielsen C.H., El Fassi D., Hasselbalch H.C., et al. B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy: the latest addition to an expanding family. Expert Opin Biol Ther 2007, 7(7):1061-1078.
66. Vannucchi G., Campi I., Bonomi M., et al. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. Clin Exp Immunol 2010, 161(3):436-443.
67. Salvi M., Vannucchi G., Campi I., et al. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin Immunol 2009, 131(2):360.
68. El Fassi D., Banga J.P., Gilbert J.A., et al. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol 2009, 130(3):252.
69. Silkiss R.Z., Reier A., Coleman M., et al. Rituximab for thyroid eye disease. Ophthal Plast Reconstr Surg 2010, 26(5):310-314.
70. Salvi M., Vannucchi G., Campi I., et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 2006, 154(4):511.
71. Salvi M., Vannucchi G., Campi I., et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007, 156:33-40.
72. El Fassi D., Nielsen C.H., Hasselbalch H.C., et al. Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 2006, 16:709-710.
73. Khanna D., Chong K.K., Afifiyan N.F., et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 2010, 117:133-139. e2.
74. Krassas G.E., Stafilidou A., Boboridis K.G. Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids. Clin Endocrinol (Oxf) 2010, 72:853-855.
75. El Fassi D., Nielsen C.H., Kjeldsen J., et al. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut 2008, 57:714-715.
76. Marcocci C., Kahaly G.J., Krassas G.E., et al. European Group on Graves' Orbitopathy. Selenium and the course of mild Graves' orbitopathy. N Engl J Med 2011, 364(20):1920.
77. van Steensel L., van Hagen P.M., Paridaens D., et al. Whole orbital tissue culture identifies imatinib mesylate and adalimumab as potential therapeutics for Graves' ophthalmopathy. Br J Ophthalmol 2011, 95(5):735-738.
78. Tian X.L., Yao W., Guo Z.J., et al. Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycin. Chin Med Sci J 2006, 21(3):145-151.
79. Kim H., Choi Y.H., Park S.J., et al. Antifibrotic effect of Pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels. Invest Ophthalmol Vis Sci 2010, 51(6):3061-3066.
80. Sakula A. Henry Hyde Salter (1823-71): a biographic sketch. Thorax 1985, 40:887-888.
81. Asthma Facts and Figures. Available at: Accessed March 20, 2012. http://www.aafa.org.
82. Mutius E.C., Drazen J.M. A patient with asthma seeks medical advice: 1828, 1928 and 2012. N Engl J Med 2012, 366:827-834.
83. Shalev I., Schmelze M., Robson S.C., et al. Making sense of regulatory T-cell suppressive function. Semin Immunol 2011, 23:282-292.
84. Holgate S.T. Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches. J Allergy Clin Immunol 2011, 128:495-505.
85. Kim H., Mazza J. Asthma. Allergy Asthma Clin Immunol 2011, 7(Suppl 1):S2.
86. Noon L. Prophylactic inoculation against hay fever. Lancet 1911, 1:1572.
87. Abramson M.J., Puy R.M., Weiner J.M. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003, 4. CD001186.
88. Calamita Z., Saconato H., Pela A.B., et al. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized clinical trials using the Cochrane collaboration method. Allergy 2006, 61:1162-1172.
89. Calderon M.A., Casale T.B., Togias A., et al. Allergen specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011, 127:30-38. [Erratum appears in J Allergy Clin Immunol 2011;127(4):859].
90. Cox L., Nelson H., Lockey R., et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011, 127(Suppl 1):S1-S55. [Erratum appears in J Allergy Clin Immunol 2011;127(3):840].
91. Akdis C.A., Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011, 127:18-27.
92. Cox L., Larenas-Linnemann D., Lockey R.F., et al. Speaking the same language: the World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 2010, 125:569-574.
93. Smith S.L. Ten years of Orthoclone OKT3 (muromonab- CD3): a review. J Transpl Coord 1996, 6(3):109-119.
94. Hanania N.A., Alpan O., Hamilos D.L., et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011, 154:573-582.
95. Clienti S., Moijaria J.B., Basile E., et al. Monoclonal antibodies for treatment of severe asthma. Curr Allergy Asthma Rep 2011, 11:253-260.
96. de Mos M., de Bruijn A.G., Huygen F.J., et al. The incidence of complex regional pain syndrome: a population based study. Pain 2007, 129:12-20.
97. Huygen F.J., de Bruijn A.G., de Bruin M.T., et al. Evidence for local inflammation in complex regional pain syndrome type 1. Mediators Inflamm 2002, 11:47-51.
98. Uceyler N., Eberle T., Rolke R., et al. Differential expression patterns of cytokines in complex regional pain syndrome. Pain 2007, 132:195-205.
99. Goebel A., Baranowski A., Maurer K., et al. Intravenous immunoglobulin treatment of the complex regional pain syndrome. Ann Intern Med 2010, 152:152-158.